Amine-Substituted Triazole Derivatives for V1a/V2 Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart failure and renal diseases related to vasopressin receptor activity are inadequate, particularly in addressing the imbalance between V1a and V2 receptor actions, which can lead to further complications such as vasoconstriction and cardiac hypertrophy.
Innovation Solution
Development of novel amine-substituted 1,2,4-triazole derivatives that act as potent selective or dual V1a/V2 receptor antagonists to inhibit vasopressin's action, offering a therapeutic profile for treating renal and cardiovascular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If V2 receptor antagonists are used to increase water excretion, then volume homeostasis is restored, but electrolyte homeostasis may be affected
Solution Approach 1:
The patent segments the vasopressin receptor antagonism into selective V2 receptor blockade, separating water excretion function from electrolyte handling. This allows targeted inhibition of V2 receptors in the kidney to promote water excretion while leaving V1a receptors unaffected, thereby maintaining electrolyte homeostasis.
Solution Approach 2:
The compound exhibits different pharmacological selectivity at different receptor locations - preferential binding to V2 receptors in the renal collecting ducts while having minimal affinity for V1a receptors in vascular smooth muscle. This local quality difference enables water excretion without significant vasoconstrictive effects or electrolyte disturbances.
2Quantity of substance
If vasopressin levels are elevated in heart failure, then water retention occurs, but vasoconstriction and cardiac hypertrophy are exacerbated
Solution Approach 1:
The patent applies segmentation by selectively blocking V2 receptors responsible for water retention while leaving V1a receptors that mediate vasoconstriction and cardiac effects unblocked. This selective approach addresses water retention without exacerbating harmful vasoconstrictive and hypertrophic effects.
Solution Approach 2:
The patent converts the harmful effect of elevated vasopressin (water retention leading to volume overload) into a beneficial therapeutic effect by selectively blocking V2 receptors. This allows the body to excrete excess water while avoiding the harmful vasoconstrictive and hypertrophic effects that would result from non-selective blockade.
3Reliability
If current treatments are used for heart failure and renal diseases, then some symptoms are managed, but the imbalance between V1a and V2 receptor actions is not addressed
Solution Approach 1:
The patent changes the pharmacological parameter of receptor selectivity by designing compounds with preferential affinity for V2 receptors over V1a receptors. This parameter change enables selective modulation of water excretion while minimizing effects on vascular tone and cardiac function, thereby addressing the receptor action imbalance.
Data Source
AI summary
The present invention relates to novel amine substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.